Home Newsfeeds EF Hutton Reiterates Buy on Upexi, Maintains $7 Price Target

EF Hutton Reiterates Buy on Upexi, Maintains $7 Price Target

EF Hutton analyst Michael Albanese reiterates Upexi (NASDAQ:UPXI) with a Buy and maintains $7 price target.

byBenzinga Newsdesk

February 15, 2023

1 minute read

EF Hutton analyst Michael Albanese reiterates Upexi (NASDAQ:UPXI) with a Buy and maintains $7 price target.

M&A
News

ESAB Corp to Acquire the Welding Business of Linde Bangladesh, Financial Terms Undisclosed

By Benzinga Newsdesk

May 30, 6:32 AM

ESAB Corporation ("ESAB" or the "Company") (NYSE:ESAB), a focused premier industrial compounder, announced today that it has entered into an agreement to acquire Linde Industries Private Limited

ESAB

Analyst Ratings

Where Palo Alto Networks Stands With Analysts

By Benzinga Insights

September 29, 10:00 AM

Over the past 3 months, 38 analysts have published their opinion on Palo Alto Networks (NASDAQ:PANW) stock. These…

PANW

AI-Driven Growth Set To Strengthen Google’s Ad Revenue: Goldman Sachs

By Anusuya Lahiri

May 22, 12:33 PM

Google AI tools & services launch for digital advertising. AI improves ad spend, streaming video & content. Alphabet well-positioned for AI theme.

GOOG

FDA
News

Aridis Says Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective In Non-Human Primates

By Benzinga Newsdesk

August 10, 8:33 AM

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that inhaled

ARDS

EF Hutton Reiterates Buy on Upexi, Maintains $7 Price Target

Related Posts

ESAB Corp to Acquire the Welding Business of Linde Bangladesh, Financial Terms Undisclosed

Where Palo Alto Networks Stands With Analysts

AI-Driven Growth Set To Strengthen Google’s Ad Revenue: Goldman Sachs

Aridis Says Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective In Non-Human Primates